Pharma News
-
![CanSino's new crown mRNA vaccine 3+1 sequential safety protection effect is good]( "CanSino's new crown mRNA vaccine 3+1 sequential safety protection effect is good")
CanSino's new crown mRNA vaccine 3+1 sequential safety protection effect is good
2023-01-07A new generation of vaccines is about to be unveiled with better protection effect!
-
![Zejing Pharma disclosed the latest clinical trial data of jacktinib hydrochloride]( "Zejing Pharma disclosed the latest clinical trial data of jacktinib hydrochloride")
Zejing Pharma disclosed the latest clinical trial data of jacktinib hydrochloride
2023-01-05Jackettinib hydrochloride is a new JAK inhibitor drug independently developed by Zejing Pharmaceutical
-
![Medical insurance negotiation prospect: sky-high drugs, Paxlovid waiting for 'turning positive', PD-(L)1 once again chasing the deer...]( "Medical insurance negotiation prospect: sky-high drugs, Paxlovid waiting for 'turning positive', PD-(L)1 once again chasing the deer...")
Medical insurance negotiation prospect: sky-high drugs, Paxlovid waiting for 'turning positive', PD-(L)1 once again chasing the deer...
2023-01-05Today's soul bargaining talks.
-
![Domestic anti-HIV new drug, Addison Pharmaceutical's 'Inomitine Tablets' was approved for marketing!]( "Domestic anti-HIV new drug, Addison Pharmaceutical's 'Inomitine Tablets' was approved for marketing!")
Domestic anti-HIV new drug, Addison Pharmaceutical's 'Inomitine Tablets' was approved for marketing!
2023-01-05The first batch of new drugs in 2023!
-
![Nicolas Pharmaceutical, the life and death bureau of innovative drug patents]( "Nicolas Pharmaceutical, the life and death bureau of innovative drug patents")
Nicolas Pharmaceutical, the life and death bureau of innovative drug patents
2023-01-05Shopping malls are like battlefields, especially the war of innovative drugs, which is more cruel.
-
![The global number of new crown sequelae is estimated to be nearly 145 million, and we must be vigilant against these 'new crown sequelae' after 'Yangkang'!]( "The global number of new crown sequelae is estimated to be nearly 145 million, and we must be vigilant against these 'new crown sequelae' after 'Yangkang'!")
The global number of new crown sequelae is estimated to be nearly 145 million, and we must be vigilant against these 'new crown sequelae' after 'Yangkang'!
2023-01-05With an average follow-up of 4 months, 45% of new crown recoveries still have symptoms such as fatigue and pain.
-
![Hillhouse, source peak blessing! Navitas' strongest challenger, why does 20 million profit support a valuation of 4 billion+?]( "Hillhouse, source peak blessing! Navitas' strongest challenger, why does 20 million profit support a valuation of 4 billion+?")
Hillhouse, source peak blessing! Navitas' strongest challenger, why does 20 million profit support a valuation of 4 billion+?
2023-01-05The dislocation competition of Saifen Technology: a leader in the field of analytical chromatography
-
![Hutchison Pharmaceutical's Solopinib China Phase III patient enrollment was completed]( "Hutchison Pharmaceutical's Solopinib China Phase III patient enrollment was completed")
Hutchison Pharmaceutical's Solopinib China Phase III patient enrollment was completed
2023-01-05Solopinib is a novel, researchable, selective small molecule oral splenic tyrosine kinase ("Syk") inhibitor.
-
![Benefiting female patients, Hambetai ® Supplementary Application for New Indications for Gynecologic Oncology was approved]( "Benefiting female patients, Hambetai ® Supplementary Application for New Indications for Gynecologic Oncology was approved")
Benefiting female patients, Hambetai ® Supplementary Application for New Indications for Gynecologic Oncology was approved
2023-01-05Hambetel ® is once again approved for the treatment of gynecological oncology, covering a wider range of patients.
-
![2022 License-out inventory: 44 cross-border transactions, with a single maximum amount of nearly US$10 billion; New projects, new technologies...]( "2022 License-out inventory: 44 cross-border transactions, with a single maximum amount of nearly US$10 billion; New projects, new technologies...")
2022 License-out inventory: 44 cross-border transactions, with a single maximum amount of nearly US$10 billion; New projects, new technologies...
2023-01-04Cross-border license-out transaction inventory of Chinese pharmaceutical companies in 2022.
-
![Mabwell 9MW3011 injection was approved for clinical trials]( "Mabwell 9MW3011 injection was approved for clinical trials")
Mabwell 9MW3011 injection was approved for clinical trials
2023-01-04Mabwell announced that the clinical trial application of its self-developed 9MW3011 injection was officially approved by the National Medical Products Administration (NMPA), and clinical trials were carried out for iron overload-related indications.
-
![The battle for new crown oral drugs, attack on RdRp inhibitors]( "The battle for new crown oral drugs, attack on RdRp inhibitors")
The battle for new crown oral drugs, attack on RdRp inhibitors
2023-01-04In the past year, the popularity of domestic new crown oral drugs was almost entirely supported by the concept of 3CL protease inhibitors.
-
![CSPC Pharmaceutical Group's first-in-class drug was approved for clinical trial for another indication]( "CSPC Pharmaceutical Group's first-in-class drug was approved for clinical trial for another indication")
CSPC Pharmaceutical Group's first-in-class drug was approved for clinical trial for another indication
2023-01-03ALMB-0166 has been approved for clinical trials for the treatment of osteoarthritis
-
![BeiGene: Bizean new indication marketing authorization application accepted]( "BeiGene: Bizean new indication marketing authorization application accepted")
BeiGene: Bizean new indication marketing authorization application accepted
2023-01-03Approved for the treatment of first-line unresectable or metastatic hepatocellular carcinoma.
-
![Baiji gene autologous anti-CLL-1 chimeric antigen receptor T cell injection was approved for clinical practice]( "Baiji gene autologous anti-CLL-1 chimeric antigen receptor T cell injection was approved for clinical practice")
Baiji gene autologous anti-CLL-1 chimeric antigen receptor T cell injection was approved for clinical practice
2023-01-03The indication is relapsed and refractory acute myeloid leukemia (r/r AML).
-
![Legend Biologics submitted a new drug marketing application for cedarchicel and was accepted by the China Food and Drug Administration]( "Legend Biologics submitted a new drug marketing application for cedarchicel and was accepted by the China Food and Drug Administration")
Legend Biologics submitted a new drug marketing application for cedarchicel and was accepted by the China Food and Drug Administration
2023-01-03Cedakicel brings clinical benefit to patients with relapsed or refractory multiple myeloma.
-
![Targeting c-Met, Remegen ADC drug RC108 was approved for clinical use in the United States for the treatment of solid tumors]( "Targeting c-Met, Remegen ADC drug RC108 was approved for clinical use in the United States for the treatment of solid tumors")
Targeting c-Met, Remegen ADC drug RC108 was approved for clinical use in the United States for the treatment of solid tumors
2023-01-03For the treatment of patients with solid tumors with positive C-Met expression
-
![With a market size of 119.1 billion yuan, the fantasy journey of the 'water seller' in the pharmaceutical industry]( "With a market size of 119.1 billion yuan, the fantasy journey of the 'water seller' in the pharmaceutical industry")
With a market size of 119.1 billion yuan, the fantasy journey of the 'water seller' in the pharmaceutical industry
2023-01-03Opportunities and Crises in the CDMO Industry.
-
![2022 Inventory | 416 domestic improved new drugs were accepted, including Qilu, Chia Tai Tianqing, Yueyang...]( "2022 Inventory | 416 domestic improved new drugs were accepted, including Qilu, Chia Tai Tianqing, Yueyang...")
2022 Inventory | 416 domestic improved new drugs were accepted, including Qilu, Chia Tai Tianqing, Yueyang...
2023-01-03What is the application status of domestic improved new drugs in 2022? How's it going?
-
![2022 inventory: A-share medicine and equipment fell top 30! CanSino, Gan & Lee Pharmaceutical, Kailaiying...]( "2022 inventory: A-share medicine and equipment fell top 30! CanSino, Gan & Lee Pharmaceutical, Kailaiying...")
2022 inventory: A-share medicine and equipment fell top 30! CanSino, Gan & Lee Pharmaceutical, Kailaiying...
2023-01-03Chunjiang plumbing "stock" prophet, stock volatility has always been the wind vane of the market.
-
Pharmaceutical Industry Overview
The magazine has been officially published in August 2024 and will be distributed at CPHI Korea 2024 and CPHI Milan 2024. It could be permanently available for download online. We sincerely invite you to join us in the publicity, making full use of the influence of the journal to promote your brand & products, expand your corporate influence in the global market.Published in: Aug. 2024
Hot News
-
Top 10 Global CDMO Rankings in 2022
-
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
-
Forecast of TOP 10 global best-selling drugs in 2021
-
Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
-
China State Drug Administration officially approved Semaglutide for type 2 diabetes
-
Top 30 best-selling oncology drugs in the world in 2020
-
Breaking News! China's First KRAS G12D Inhibitor Approved for Clinical Use
-
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial
-
AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
